Centogene N.V. (CNTGF) - Total Assets
Based on the latest financial reports, Centogene N.V. (CNTGF) holds total assets worth $77.16 Million USD as of December 2023. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Centogene N.V. - Total Assets Trend (2020–2023)
This chart illustrates how Centogene N.V.'s total assets have evolved over time, based on quarterly financial data. Also see Centogene N.V. (CNTGF) total market value for the company's overall valuation and market capitalisation.
Centogene N.V. - Asset Composition Analysis
Current Asset Composition (December 2023)
Centogene N.V.'s total assets of $77.16 Million consist of 57.1% current assets and 43.0% non-current assets. Review how much debt does Centogene N.V. carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.6% |
| Accounts Receivable | $16.80 Million | 21.8% |
| Inventory | $2.46 Million | 3.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $6.85 Million | 8.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Centogene N.V.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Centogene N.V. stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Centogene N.V.'s current assets represent 57.1% of total assets in 2023, a decrease from 64.6% in 2020.
- Cash Position: Cash and equivalents constituted 23.6% of total assets in 2023, down from 28.8% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, unchanged from 8.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 21.8% of total assets.
Centogene N.V. Competitors by Total Assets
Key competitors of Centogene N.V. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
USA | $481.49 Million |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥13.79 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$1.38 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$584.37K |
Centogene N.V. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 1.45 | - |
| Quick Ratio | 0.96 | 1.37 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $653.00K | $12.01 Million | - |
Centogene N.V. - Advanced Valuation Insights
This section examines the relationship between Centogene N.V.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -16.9% |
| Total Assets | $77.16 Million |
| Market Capitalization | $3.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values Centogene N.V.'s assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Centogene N.V.'s assets decreased by 16.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Centogene N.V. (2020–2023)
The table below shows the annual total assets of Centogene N.V. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $77.16 Million | -16.87% |
| 2022-12-31 | $92.81 Million | +1.84% |
| 2021-12-31 | $91.14 Million | -39.21% |
| 2020-12-31 | $149.92 Million | -- |
About Centogene N.V.
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA … Read more